English

PharmNovo submits CTA for neuropathic pain drug candidate

Report this content

PharmNovo has submitted a clinical trial application (CTA) to the Swedish Medical Products Agency and Ethical Review Authority to start a phase I study of its neuropathic pain drug candidate PN6047. The company's preclinical program has been completed with good results regarding safety and efficiency. The drug candidate is thus ready to be tested in a first-in-human study.

Neuropathic pain, or nerve pain, affects nearly ten percent of the population in Europe and the United States. It is a difficult-to-treat form of pain that often develops into a chronic condition and significantly impairs people's quality of life. The drug candidate PN6047 from PharmNovo is an entirely new type of drug which has effectively relieved nerve pain in animal models without the adverse side effects associated with the drugs on the market today.

The primary goal of the clinical study is to investigate the safety and tolerability of the candidate PN6047. The phase I study will be carried out by Clinical Trial Consultants AB (CTC, based in Uppsala, Sweden) and will include about a hundred healthy volunteers.

Per von Mentzer, CEO of PharmNovo, comments:

"With great pleasure and satisfaction, we can announce that our first clinical trial application has been submitted. The application results from many years of dedicated preclinical work and marks an essential milestone in developing our candidate for the treatment of neuropathic pain. I thank the team whose hard work and commitment have made it possible to achieve this. We await information from the authorities and look forward to starting the clinical trial in 2022."

For more information, please contact:

Per von Mentzer, CEO
Phone +46 705 44 32 50
Email: per.von.mentzer@pharmnovo.com

About PharmNovo

PharmNovo AB is a clinical phase pharmaceutical company focused on developing safe and effective drugs for neuropathic pain. In this area, there is currently a lack of sufficient treatment. The company's drug candidate, PN6047, has effectively reduced nerve pain in animal models in preclinical studies. The company also sees clinical potential in other areas such as migraine, anxiety/depression, and chronic cough. PharmNovo, headquartered in Medicon Village in Lund, Sweden, was founded in 2008 by Dr. Bengt von Mentzer, who has more than 30 years of experience in drug development and pain research at Astra Zeneca. The team comprises prominent researchers in academia and industry, and the company has an extensive international network of leading expert advisors. To learn more, visit pharmnovo.com.

Tags:

Life Science neuropathic pain Chronic Pain drugs Pharmnovo

Subscribe

Media

Media

Documents & Links

Quick facts

The Swedish pharmaceutical company PharmNovo has submitted a CTA to the Swedish Medical Products Agency and Ethical Review Authority to start a phase I study of its neuropathic pain drug candidate PN6047. Neuropathic pain, or nerve pain, affects nearly ten percent of the population in Europe and the United States. It is a difficult-to-treat form of pain that often develops into a chronic condition and significantly impairs people's quality of life. The drug candidate PN6047 from PharmNovo is an entirely new type of drug which has effectively relieved nerve pain in animal models without the adverse side effects associated with the drugs on the market today.
Tweet this

Quotes

With great pleasure and satisfaction, we can announce that our first clinical trial application has been submitted. The application results from many years of dedicated preclinical work and marks an essential milestone in developing our candidate for the treatment of neuropathic pain. I thank the team whose hard work and commitment have made it possible to achieve this. We await information from the authorities and look forward to starting the clinical trial in 2022.
Per von Mentzer, CEO of PharmNovo